Trial Profile

Phase 2 Trial of a WT1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Galinpepimut S (Primary)
Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

28 Nov 2018 Status changed from active, no longer recruiting to completed.
27 Feb 2018 Primary endpoint has been met. (To assess the efficacy of the WT1 peptide vaccine administered to patients in CR from AML.), as reported in a Sellas Life Sciences media release.
27 Feb 2018 According to a Sellas Life Sciences media release, results from this trial published in the current issue of Blood Advances.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com